STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2020

Sep 14, 2020

==> picture [118 x 47] intentionally omitted <==

September 14, 2020

BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza , Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR

Dear Sirs,

Sub: Strides Press Release dated September 14, 2020 titled “ Strides unveils SteriScience as its dedicated arm for sterile injectables”

With reference to above, please also find enclosed the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the said transaction.

Thanks and Regards, For Strides Pharma Science Limited

==> picture [131 x 58] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [85 x 82] intentionally omitted <==

==> picture [480 x 50] intentionally omitted <==

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

==> picture [110 x 51] intentionally omitted <==

Strides unveils SteriScience as its dedicated arm for sterile injectables

Sr.No	Particulars	Remarks
1.	Name of the Target entity, details in briefsuch as size, turnover etc.	SteriScience Pharma Private Limited(‘SteriScience’) is a newly incorporatedcompany by Strides’ Promoters family officeon August 29, 2020.Consequently, Mr. Arun Kumar, Founder andChairperson of Strides is interested inSteriScience.
2.	Whether the acquisition of the Target entityfalls within the related party Transactionand whether the promoter/ promotergroup/group companies have any interest inthe entity being acquired?If yes, nature of interest and details thereofand whether the same is done at “armslength”
3.	Industry to which Target entity beingacquired belongs	Pharmaceuticals (Injectibles)
4.	Objects and effects of acquisition	Investment in SteriScience will allow Stridesto leverage its rich expertise and experience inthe high-value injectables business.SteriScience is designed for a global foray insterile injectables leveraging the group’s richexperience in the domain.It will be a lighter, faster and yet morevaluable platform with a robust B2C strategythat bodes well with the industry opportunity.
5.	Brief details of any governmental orregulatory approvals required for theacquisition	None

==> picture [90 x 88] intentionally omitted <==

==> picture [110 x 51] intentionally omitted <==

6.	Indicative time period for completion of theacquisition	Investment to be made over a period of 24months
7.	Nature of consideration - Whether cashconsideration or share swap and details ofthe same.	Cash Consideration
8.	Cost of acquisition or the price at which theshares are acquired	Strides to invest INR 1,350 Million over thenext 24 months
9.	Percentage of shareholding/ controlacquired and/ or number of shares acquired	Strides to have a controlling stake inSteriScience with ~54% ownership
10.	Brief background about the entity acquired in terms of:
a.	Products/ line of business acquired	Injectables
b.	Date of incorporation	August 29, 2020
c.	History of last 3 years turnover	Not Applicable as SteriScience is a newlyincorporated Company.
d.	Country in which the acquired entity haspresence	India
e.	Any other significant information	-

==> picture [90 x 88] intentionally omitted <==